NCT04586231 2026-03-05
MK-6482-011
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
Clinical Trials
9 trialsNCT04626479 2026-02-12
MK-3475-03A
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT05468697 2026-01-23
MK-6482-024
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT05030506 2025-12-18
MK-6482-010
Merck Sharp & Dohme LLC
Phase 1 Active not recruiting
NCT05899049 2025-11-10
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05239728 2025-08-14
MK-6482-022
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04626518 2025-07-25
KEYMAKER-U03
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT02974738 2025-07-10
MK-6482-001
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Active not recruiting
NCT04195750 2025-04-29
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting